Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

3 treatments under study, led by Puressentiel Protective Nasal Spray

Research Leaders

5 sponsors active, led by Institut National de la Santé Et de la Recherche Médicale, France

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Completed2
Recruiting1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT01678222CompletedPrimary

The COX-2 Gene and the Immune System

NCT05584488Recruiting

Allergy and Immunology Natural History Study

NCT04700852Not ApplicableUnknown

Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis

NCT03644680Not ApplicableCompleted

Changes in Adaptive Immune Responses and Effector Cell Responses Upon Nasal Allergen Exposure - a Pilot Study

Showing all 4 trials

Research Network

Common Treatments

  • Puressentiel Protective Nasal Spray1
  • Nasal Provocation With Birch Extract1
  • Nasal Provocation With Nacl 091

Active Sponsors

  • Institut National de la Santé Et de la Recherche Médicale, France1
  • Puressentiel1
  • National Institute of Environmental Health Sciences (NIEHS)1
  • Columbia University1
  • Medical University of Vienna1

Top Investigators

Related Conditions

  • Immune Dysregulation Disorder1
  • Asthma1
  • Allergic Rhinitis Due To Grass Pollen1
  • Allergic Rhinitis1
  • Immune Deficiency1

Activity Timeline